

# UnitedHealthcare Pharmacy - July 1 PDL Report

## Fully Insured Customers on the Advantage PDL

The July 1, 2012 Prescription Drug List (PDL) and pharmacy benefit updates represent a small percentage of all prescriptions, with the exception of Lipitor – no medications in the top 100 by utilization – but create significant value for our customers. These decisions are designed to drive the greatest total health care value, while preserving affordable choice for members, with the least amount of disruption. Please see the “Decision Definitions Key” tab for symbol and program descriptions. For a complete list of clinical program changes, list of alternative drugs, or member communication materials, please contact your UnitedHealthcare representative.

Decisions	Assessment	Effective Date
Lipitor Update		
3 ▶ 2 <b>atorvastatin</b> (generic Lipitor)	Atorvastatin (generic Lipitor) launched last Nov. and is anticipated to decrease in price when their exclusivity expires and other manufacturers enter the market, around June 1, 2012. At that time, Lipitor will move to Tier 3 and the generic will move to Tier 1. <b>Most members will pay the same copayment.</b> Point-of-Sale messaging will direct the pharmacist to dispense the lowest cost option for the member unless their physician does not allow generic substitutions. We will continue to monitor the generic price and reevaluate its tier placement.	6/1/2012 or earlier
2 ▶ 3 <b>Lipitor</b>		
Therapeutic Class Overview - Diabetes		
3 ▶ 1 <b>One Touch Verio</b>	<p><b>New combination medications and products to market expands therapy options and alternatives, providing an opportunity to lower overall class costs.</b></p> <ul style="list-style-type: none"> <li>▶ <b>One Touch Verio</b> - joins other One Touch test strips in Tier 1 as no generic alternatives are available.</li> <li>▶ <b>Jentadueto, Kombiglyze XR, Onglyza, and Tradjenta</b> - newly negotiated prices offer sufficient value for these brand medications and products to be down-tiered, and provide affordable alternatives to medications moving into the Select Designated Pharmacy Program.</li> <li>▶ <b>Janumet and Januvia</b> will be up-tiered to Tier 3 and will be placed in the Select Designated Pharmacy Program.</li> <li>▶ <b>ActoplusMet XR, Apidra, Aprida Solostar</b> - As the more expensive options within the class, these medications will be placed in the Select Designated Pharmacy Program.</li> </ul>	7/1/2012
3 ▶ 2 <b>Jentadueto, Kombiglyze XR, Onglyza, Tradjenta</b>		
2 ▶ 3 <b>Janumet, Januvia</b>		
DP <b>ActoplusMet XR, Apidra, Aprida Solostar</b>		
Therapeutic Class Overview - Pain		
3 <b>Abstral</b> (cancer pain)	<p><b>The pain medication class continues to require management with the launch of new formulations and brand options that offer limited to no clinical value.</b></p> <ul style="list-style-type: none"> <li>▶ <b>Abstral and Nucynta ER</b> - Upon review, these medications, previously excluded at launch, will now be covered in Tier 3 under the pharmacy benefit because they offer sufficient value.</li> <li>▶ <b>Fentora</b> - Is the most expensive option in the class, where medications cost thousands of dollars. It has significantly increased in price, over three times more than the Tier 2 generic that contains the same active ingredient, fentanyl citrate.</li> <li>▶ <b>Zolvit</b> - Previously excluded at launch, is a new concentration of a generic oral solution available in Tier 1 (hydrocodone / acetaminophen solution), combining Tylenol with a narcotic, yet costs over five times more.</li> </ul>	7/1/2012 or earlier
✗ <b>Fentora</b> (cancer pain - 2007 Rider)		
3 <b>Nucynta ER</b> (pain)		
✗ <b>Zolvit</b> (pain - 2007 Rider)		

Decisions		Assessment	Effective Date
Therapeutic Class Overview - Skin Conditions			
	<b>BenzEfoam Ultra</b> (acne - 2004 Rider) <b>Delos Cleanser, Lotion</b> (acne - 2004 Rider)	<p><b>Skin conditions, in particular acne, continue to be one of the areas our PDL Management Committee develops strategies for given the number of lower-cost prescription and over-the-counter alternatives.</b></p> <p>▶ <b>BenzEfoam Ultra and Delos</b> - Previously excluded at launch, these benzoyl peroxide medications offer little value with therapeutically equivalent over-the-counter forms available.</p> <p>▶ <b>Duac</b> - Priced at a premium to Tier 1 generic clindamycin / benzoyl peroxide, its continued cost increases have diminished its overall value in this crowded category.</p> <p>▶ <b>Pramosone E</b> - Contains the same active ingredient as Pramoxone in a slightly different cream formulation yet is twice as expensive as its therapeutic equivalent, Tier 1 generic Pramoxone.</p> <p>▶ <b>Rosadan Kit</b> - Previously excluded at launch as a multiple product package and far more expensive than its individual components, this kit offers no additional value.</p>	7/1/2012
	<b>Duac, Duac CS</b> (acne - 2007 Rider)		
	<b>Pramosone E</b> (dermatitis - 2007 Rider)		
	<b>Rosadan Kit</b> (rosacea - 2007 Rider)		
Therapeutic Class Overview - Testosterone Replacement			
	<b>Axiron</b> (2007 Rider) <b>Fortesta</b> (2007 Rider)	<b>Aggressive marketing around the use of testosterone has significantly increased use of these male hormone replacements and overall class costs.</b> Both excluded at launch, Tier 2 Testim is a better value. Other Tier 2 alternatives exist as well.	7/1/2012
Additional Down-Tiers			
	<b>Incivek</b> (hepatitis C) <b>Nuedexta</b> (neurological disorder)	Both of these medications offer sufficient health care value to warrant a lower tier placement. These decisions may be implemented prior to July 1, 2012 so members can take immediate advantage of the cost savings.	7/1/2012 or earlier
Additional Exclusions*			
	<b>Atelvia</b> (osteoporosis - 2007 Rider)	Atelvia, previously excluded at launch, is a delayed-release version of Actonel yet is <b>almost nine times more expensive</b> than a generic alternative in Tier 1. <b>A generic version of Actonel is also expected in 2014.</b>	7/1/2012
	<b>Kapvay</b> (ADHD - 2007 Rider)	Kapvay, previously excluded at launch, is an extended-release version of Tier 1 clonidine yet is <b>over 18 times more expensive.</b> Prior to Kapvay being approved, ADHD guidelines already recommended clonidine as monotherapy or adjunct therapy.	7/1/2012
	<b>Nexiclon XR</b> (high blood pressure - 2007 Rider)	Nexiclon XR, previously excluded at launch, is also an extended-release version of Tier 1 clonidine, which is the same active ingredient for Kapvay (above) and has been available since 1974 to treat high blood pressure, yet <b>Nexiclon is over 58 times more expensive.</b>	7/1/2012
	<b>Zolpimist</b> (sleep aid - 2007 Rider)	Zolpimist, previously excluded at launch, is an oral spray formulation of Tier 1 zolpidem (generic Ambien), but <b>priced seven times more.</b>	7/1/2012

\* For customers that implemented the Exclude at Launch Program, the green icons indicate which medications were excluded at launch and will have minimal to no member impact. For customers that did not, medications are in Tier 3.

# UnitedHealthcare Pharmacy - July 1 PDL Report for Contraceptives

## Health Care Reform Update for Fully Insured Customers on the Advantage PDL

Beginning August 1, 2012, UnitedHealthcare will implement several tier changes as part of Health Care Reform. We are required to provide coverage for medications:

- ▶ in Tier 1
- ▶ at \$0 Cost Share
- ▶ from each of these categories
  - Emergency (e.g. Plan B)
  - Hormonal (e.g. Oral or other route)
  - Barrier (e.g. diaphragm)

Each unique progestin contraceptive medication will be represented in Tier 1, making sure women have access to each type of contraceptive.

Decisions	Assessment	Effective Date
Health Care Reform - Hormonal Contraceptive Update		
3 ▶ 1	<b>ella, Plan B</b> (emergency contraceptives)	As part of health care reform, these medications will be down-tiered to Tier 1 and available at zero cost share to the member.
2 ▶ 1	<b>Natazia</b>	
3 ▶ 1	<b>Yasmin</b>	
PDL Management - Hormonal Contraceptive Update		
1 ▶ 2	<b>Azurette, Balziva, Briellyn, Junel, Kariva, Microgestin, Ogestrel, Zenchent</b>	With multiple medications in Tier 1 at zero cost share, we are moving the following medications to a higher tier since there are higher value options available in Tier 1.
		7/1/12

**Please Note:** You may need to add language to your Summary Plan Description (SPD) in order to implement some updates. Ask your UnitedHealthcare representative if you need assistance updating your SPD.

**For more information about these pharmacy benefit updates, please visit [uhc.com/pharmacy](http://uhc.com/pharmacy) or contact your UnitedHealthcare representative.**

### Decisions Definitions Key

Key	Decision	Definition
2 ▶ 1	<b>Down-tiers</b>	Down-tiers refer to medications that move to a lower tier, which can occur at any time throughout the year to provide members with immediate cost savings.
2 ▶ 3	<b>Up-tiers</b>	Up-tiers refer to medications that move to a higher tier because they offer less health care value (either clinically and/or financially) than similar medications in their therapeutic classes.
2	<b>New Tier Placements</b>	New tier placements occur for medications that have been previously excluded at launch, but now offer sufficient health care value to have a tier placement.
DP	<b>Select Designated Pharmacy</b>	The Select Designated Pharmacy Program is a 2004/2007 Rider capability. Members on the high-cost, maintenance drugs in this program will no longer be able to fill their prescription at retail and obtain network benefits. They will be given three options to save: move to lower cost retail options, move to mail, or both.
✗	<b>Exclusions</b>	We do not make the decision to exclude medications from benefit coverage lightly. A medication is only excluded when it offers no clinical value over other options in its class and its exclusion can be leveraged to achieve significant savings for our customers while preserving affordable choices for members.
✗	<b>Continued Exclusions</b> (Previously Excluded at Launch)	These exclusions will have little to no member impact since the medication has been excluded at launch.

This does not apply to PacifiCare business administered by OptumRx. UnitedHealthcare® and the dimensional U logo are registered marks owned by UnitedHealth Group Incorporated. All branded medications are trademarks or registered trademarks of their respective owners.

M49070-L 3/12 © 2012 United HealthCare Services, Inc.